On Janaushadhi Diwas this year (i.e., March 7th, 2022), Prime Minister Shri Narendra Modi stated that the poor and the middle-class benefited from the 'Jan Aushadhi Kendras' that were set up to provide generic drugs at affordable prices. He said that the poor and the middle class saved around Rs.13,000 crore through these stores during the COVID-19 pandemic. In the wake of COVID 19 crisis, the 'Bureau of Pharma PSUs of India'...

-TheWire.in * The Parliamentary standing committee on chemicals and fertilisers has produced a report highlighting gaps in the availability of COVID-19 drugs and devices during the pandemic. * The committee has asked the national government why PSUs didn’t receive licenses to make COVID drugs when private manufacturers did. * The MPs on the committee also spotlighted widespread irrational drug use in COVID-19 management, despite the existence of a standard treatment protocol. New Delhi: The...

-PTI/ NDTV.com The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a campaign launched by the Department of Pharmaceuticals to provide quality medicines at affordable prices to the masses New Delhi: Prime Minister Narendra Modi said the poor and the middle class have benefitted from the 'Jan Aushadhi Kendras', set up to provide generic drugs at affordable prices, and they saved about ₹ 13,000 crore through the stores. He also interacted with 'Jan Aushadhi...

In the month of April this year, there has been an unprecedented upsurge in daily new cases and daily new deaths in the country due to Covid-19. States, which reported large increases in daily new cases and daily new deaths, are Maharashtra, Kerala, Karnataka, Delhi and Uttar Pradesh, to name but a few.   Data accessed from https://www.covid19india.org/, which is a crowdsourced platform and an independent aggregator of daily Covid-19 figures and...

-The Times of India NEW DELHI: In what is being seen as an attempt to delay launch of low priced generic medicines, multinational drug makers have asked the government to create a registry providing information about all drug applications pending manufacturing and marketing approval. The proposal, if accepted by the government, will help ‘big pharma’ pre-emptively challenge generic drug makers in court for allegedly infringing upon their patents and in turn blocking...